486 related articles for article (PubMed ID: 18173016)
1. [Our experience with linesolid usage in newborn children].
Atanasova V; Slavkova N; Rosmanova R
Akush Ginekol (Sofiia); 2007; 46 Suppl 1():60-2. PubMed ID: 18173016
[TBL] [Abstract][Full Text] [Related]
2. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of linezolid in liver transplant patients.
Radunz S; Juntermanns B; Kaiser GM; Treckmann J; Mathe Z; Paul A; Saner FH
Transpl Infect Dis; 2011 Aug; 13(4):353-8. PubMed ID: 21355969
[TBL] [Abstract][Full Text] [Related]
4. Experience with linezolid therapy in children with osteoarticular infections.
Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
[TBL] [Abstract][Full Text] [Related]
5. [The first clinical experiences in Hungary with a new effective antibiotic (linezolid) effective against Gram-positive infections].
Pulay I; Konkoly TM; Zsirka KA; Csapó Z; Flautner L; Tihanyi T
Orv Hetil; 2003 Jan; 144(1):29-33. PubMed ID: 12635350
[TBL] [Abstract][Full Text] [Related]
6. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
7. Linezolid for the treatment of adults with bone and joint infections.
Falagas ME; Siempos II; Papagelopoulos PJ; Vardakas KZ
Int J Antimicrob Agents; 2007 Mar; 29(3):233-9. PubMed ID: 17204407
[TBL] [Abstract][Full Text] [Related]
8. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
9. Linezolid for the treatment of complicated skin and skin structure infections in children.
Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
[TBL] [Abstract][Full Text] [Related]
10. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections.
Nguyen S; Pasquet A; Legout L; Beltrand E; Dubreuil L; Migaud H; Yazdanpanah Y; Senneville E
Clin Microbiol Infect; 2009 Dec; 15(12):1163-9. PubMed ID: 19438638
[TBL] [Abstract][Full Text] [Related]
12. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
13. Use of linezolid in children: an overview of recent advances.
Velissariou IM
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
Wilcox MH
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of linezolid in children.
Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.
Babcock HM; Ritchie DJ; Christiansen E; Starlin R; Little R; Stanley S
Clin Infect Dis; 2001 May; 32(9):1373-5. PubMed ID: 11303275
[TBL] [Abstract][Full Text] [Related]
17. Use of linezolid in pediatrics: a critical review.
Dotis J; Iosifidis E; Ioannidou M; Roilides E
Int J Infect Dis; 2010 Aug; 14(8):e638-48. PubMed ID: 20106697
[TBL] [Abstract][Full Text] [Related]
18. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
[TBL] [Abstract][Full Text] [Related]
19. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
[TBL] [Abstract][Full Text] [Related]
20. [Linezolid in the treatment of gram positive coccal infections in critical patients].
Alvarez-Lerma F
Rev Esp Quimioter; 2010 Mar; 23(1):1-3. PubMed ID: 20232017
[No Abstract] [Full Text] [Related]
[Next] [New Search]